Dissemin is shutting down on January 1st, 2025

Published in

Dove Press, Core Evidence, p. 43

DOI: 10.2147/ce.s13838

Links

Tools

Export citation

Search in Google Scholar

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma

Journal article published in 2011 by Salvia Jain, Catherine Diefenbach ORCID, Jasmine Zain, Owen A. O’Connor
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Proteasome inhibition forms the cornerstone of antimyeloma therapy. The first-in-class proteasome inhibitor, bortezomib, either alone or in combination with other chemotherapeutic agents, induces high overall response rates and response qualities in patients with clinically and molecularly defined high-risk disease. However, resistance to bortezomib and neurotoxicity associated with the treatment remain challenging issues. Carfilzomib is a novel, well tolerated, irreversible proteasome inhibitor with minimal neurotoxicity. Carfilzomib demonstrates promising activity in myeloma patients who are refractory to bortezomib and immunomodulatory agents. This review focuses on the pharmacology, safety, and efficacy of carfilzomib for the treatment of multiple myeloma in bortezomib-naïve and bortezomib-exposed populations.